obesity drug news today glp-1 october 2025 therapies are changing care. What does WHO recommend? Here's what you need to know Alarming rise in weight loss

Your physician is best positioned to recommend which is appropriate for your specific situation

Analysis of Obesity GLP-1 Market by Key Country The obesity GLP-1 market is growing rapidly across major economies, with China and the United States both recording 25.4% CAGR through 2035, driven by large treatment-eligible populations and expanding access frameworks

10.2337/dc14-2364 [DOI] [PubMed] [Google Scholar] 85.Goldenberg RM

Furthermore, CVOTs have documented the cardiovascular safety of the GLP-1 RA drug class in type 2 diabetes (Sattar et al., 2021)

So, if youve been taking a GLP-1 or considering doing so, you may be wondering if switching to generic Victoza is the right move for you

Signs and symptoms of low blood sugar may include: shakiness, sweating, headache, drowsiness, weakness, dizziness, confusion, irritability, hunger, fast heartbeat, and feeling jittery